A vaccine (illustration).
-
Frederic Sierakowski / Isopix
Cocorico in the fight against Covid-19: a French laboratory will be part of the adventure of the vaccine media from Pfizer and BioNTech.
Delpharm will indeed produce some of these vaccines.
The pharmaceutical subcontracting group announced Wednesday that it would create “40 to 60” jobs on this occasion in its Normandy plant in Saint-Rémy-sur-Avre.
“Delpharm is due to start manufacturing next April and will produce tens of millions of doses,” the laboratory said in a statement.
“It is a source of pride […] to be the first company selected to produce this vaccine in France,” said Stéphane Lepeu, Deputy CEO of the company.
Earlier Wednesday, the American Pfizer and the German BioNTech had revised upwards, to 95%, the effectiveness of their vaccine, after a first announcement on November 9 on a rate of more than 90%.
An annual turnover of 800 million euros
Owned by its management, Delpharm, which employs 4,700 people at 17 production sites, is a subcontractor for large pharmaceutical companies.
It claims to manufacture more than 900 million boxes of drugs per year, for a turnover of 800 million euros.
World
The contract for a vaccine between the European Union and Moderna concluded "in a few days"
Health
Pfizer-BioNTech vaccine 95% effective, according to comprehensive clinical trial results
Vaccine
Video
Health
Covid 19
Coronavirus
Laboratory